. WetAMDisalsoknownasneovascularAMD(nAMD), whichisthemostaggressiveform [3] .Vascularendothelial growthfactor-A (VEGF-A)hasbeenimplicatedtoplaya majorroleinthepathogenesisofthenAMD [4] [5] [6] .The treatmentfornAMDhasbeenrevolutionizedwithintravitreal anti-VEGFtherapy:ranibizumabandbevacizumab [7, 8] . Ranibizumab(Lucentis;Genentech,SouthSanFrancisco, CA,USA),ahumanizedrecombinantmonoclonal anti-VEGF-AFabfragment,isspecificallydesignedfor intravitrealtreatmentofnAMD.Whatismore,ranibizumab therapyisthefirsttreatmentfornAMDtoimprovevisionfor mostpatients,andhasbeenapprovedbytheUSFoodand DrugAdministrationforthetreatmentofnAMDonJune30, 2006 [9, 10] .Bevacizumab(Avastin;Genentech),ahumanized full-lengthmonoclonalantibodytargetingVEGF-Aandallof itsisoforms,isprimarilydesignedandapprovedforthe intravenoustreatmentofmetastaticcolorectalcancer [11, 12] .
Althoughbevacizumabisstilloff-labelfornAMDtreatment, goodefficacyandsafetyinmassesofcaseseriesand
Off-labelversusgoldstandard 陨灶贼允韵责澡贼澡葬造皂燥造熏灾燥造援 8熏晕燥援 1熏 Feb.18, 圆园15 www.IJO.cn 栽藻造押8629原愿圆圆源缘员苑圆 8629-82210956 耘皂葬蚤造押ijopress岳员远猿援糟燥皂 cost-effectivemakeitcommonlyusedin clinical treatment [13] [14] [15] .Withtheincreaseuseofunlicensed bevacizumabandgoldenstandardranibizumab,comparative studiesofthemareinprocessindifferentcountries,butthe resultsarenotconsistent. ThisMeta-analysiswasperformedtocomparetheefficacy andsafetyofbevacizumabversusranibizumabfornAMDas wellasmonthlyregimenversusasneededregimen.The resultscouldbeveryimportantinchoosingthebetterwayof treatmentfornAMD. SUBJECTSANDMETHODS SearchStrategy Medline,Embase,WebofScienceand CochraneLibraryweresearchedfrominceptionuntilJanuary 2014withnolimitationsoflanguage.Thesearchstrategy wasbasedoncombinationsofmedicalsubjectheadingsand keywords.Searchtermswere"bevacizumab","avastin", "ranibizumab","lucentis","AMD".Amanualsearchwas performedbycheckingthebibliographiesoforiginalreports andreviewarticlestoidentifystudiesnotyetincludedinthe computerizeddatabases.
Inclusion and Exclusion Criteria Inclusioninthe
Meta-analysismustmetthefollowingcriteria:1)study design:randomizedcontrolledtrials(RCTs);2)population: nAMDpatientsagedmorethan50yearsoldwithany gender;3)intervention:bevacizumabof1.25mgversus ranibizumabof0.5mg;4)outcomevariables:studiesthat haveindicatedatleastoneofbest-correctedvisualacuity (BCVA),centralretinalthickness(CRT)andadverseevents (AE)asthemainoutcomemeasures;5)duration:follow-up timewasnotlessthan1y.Exclusioncriteriawereas following:1)meetingabstracts,fulltextwithoutavailableraw data,duplicatepublications,lettersandreviews;2)studiesthat werenotRCTs;3)studiesofAMDbutnotnAMD. DateExtraction WangWJandZhangXLseparately extractedthefollowingdatafromallincludedresearches:1) characteristicsofincludedstudies:thenameoffirstauthoror thestudygroup,theyearofpublication,locationofthetrail, majorinclusioncriteria,patientsageandsexratio,number ofsubjects,variousinterventions,durationoffollow-up;2) meansandstandarddeviations(SDs)ofchangesfrom baselineinBCVAinearlytreatmentdiabeticretinopathy study(ETDRS);3)meansandSDsofchangesfrombaseline inCRTin 滋m;4)ratesofmainAEincludingdeath,arterial thromboticevent, venousthromboticevent,medical dictionaryforregulatoryactivities(MedDAR)systemorgan classand 逸1serioussystemicevent [16] .Disagreementwas resolvedbydiscussion. QualitativeAssessment Themethodologicalqualityof eachstudywasassessedusingtheJadadscoreandthe risk-of-biasassessment [17, 18] .InJadadscoreassessment,a valueof "2points","1point"or"0point"wasassignedto thetwoaspectsofrandomallocationanddoubleblind,anda valueof"1point"or"0point"wasassignedtodropoutsand withdrawals.Thetotalscorerangesfrom0to5points,and thestudieswithJadedscore 逸3pointswereconsideredto havehighquality.Intheassessmentofriskofbias,the followingparameterswereassessed:1)randomsequence generation;2)allocationconcealment; 3)blindingof participantsandpersonnel;4)blindingofoutcome assessment;5) incompleteoutcomedate;6)selective reporting;7)otherbiases.Forthequestionsabove,each parameterwasjudgedof"yes"indicatinglowriskofbias, "no"indicatinghighriskofbias,and"unclear"indicating unclearorunknownriskofbias. [20] wasunclear.Participantsandpersonnelofallstudies wereblindedexceptthatthetrailofGEFALStudyGroup [21] wasunclear.Theblindingofoutcomesassessmentwas reportedinfivestudiesandtheothertwowereunclear.
ThereweremissingdatainoutcomesinthestudiesofCATT ResearchGroup [22, 23] andIVANStudyInvestigators [24, 25] as wellasSubramanian [20] .Selectiveoutcomesreporting excluded.Removingthestudydidnotaltertheresult obtainedinpreviousanalysis. DISCUSSION Lotsofstudiesconcludedbevacizumabandranibizumabhad similarvisualandanatomicoutcomefornAMD,andthat bevacizumabwasmuchlessexpensivethanthegold standardranibizumab,allofthesegivingrisetothe widespreaduseofbevacizumab [27] [28] [29] [30] .However,thestudiesby Chang [31] andGEFALStudyGroup [21] demonstrated thattheeffectivenessofranibizumabtreatmentmeasuredby incrementalimprovementinopticalcoherencetomography parameterswassignificantly greaterthanbevacizumab treatment,meaningthatoff-labelbevacizumabwasinferior tolicensedranibizumabforanatomicresult.Andotherstudy concludedthattherewerepersisthigherratesofseriousAE withbevacizumabtreatmentthanranibizumabtreatment [23] . Henceitisstillunknownthatwhetherthetwobiologicare equivalentorwhichcertainismoreeffective.Thus,we conductedthisMeta-analysistocomparetheefficacyand safetyofintravitrealbevacizumabandranibizumabinthe andUnver [33] ,whostudiedthe relationshipbetweenvisualfunctionandanatomicchangesin thetreatmentofnAMD.Bycomparingthedifferentdosing regimensofmonthlyandasneeded,wediscoveredthatthe monthlyregimenwasmoreeffectiveinimprovingBCVA andreducingtheCRTthanasneededregimen.Thedosing regimenswerealsodiscussedbymanystudies.Haller [34] pointedoutthatasneededregimenprovidedareasonable approachtomonthlybutindividualizationoftreatment neededtocontinuetoevolve.Gupta [35] concluded monthlyadministrationachievedgreatervisualgainsthanas neededprotocol,consistentwithourresults. Ouranalysisshowedthattheincidencesofserioussystemic eventandMedDARSystemOrganClasseventinthe treatmentofbevacizumabwerestatisticallyhigherthan ranibizumab,whiletheratesofdeathandthromboticevent hadnodifference.Moreover,theratesofallAEindifferent dosingregimensmadenoodds.Thereasonmayberelatedto thenotexactlysamecharacteristicsofthetwodrugs,butstill uncertain.Althoughbevacizumablikeranibizumabisa monoclonalantibodyinhibitingallisoformsofVEGF, bevacizumabisalargermoleculeof149KDandhaslonger half-lifeof17-21dthanranibizumabweightof48.38KDand half-lifeof3d [36] .Carneiro [37] concludedthatintravitreal bevacizumabsignificantlyreducedVEGFplasmalevelsuntil 28dafterintravitrealinjectioninpatientswithnAMDwhile ranibizumabdidnotachieveasignificantplasmaVEGF reductionatthesametime-point.Thesealerttothepotential systemicsafetydifferencesbetweenthetwodrugsafter intravitrealadministration.Inaddition,VEGFisimportant forreperfusioninthebody,andpatientswithlowersystemic levelofVEGF-Aarelikelytohavelowerthresholdsof tolerancetoanti-VEDFagentsandareathigherriskfor systemicAE [38] . Inourinclusion,theproportionofpatientswithpigment detachment(PED)associatedwithnAMDwassimilarin bevacizumabgroupandranibizumabgroupatbaselineinthe studybyGEFALStudyGroup [21] ,andtherewasnospecific descriptionoftheproportionofpatientswithPEDatbaseline inotherstudies.PED,whichreferstoseparationofthe retinalpigmentepithelium(RPE)fromtheunderlyingBruch membrane,iscommoninpatientswithAMD.InnAMD, occultchoroidalneovascularization(CNV)arefrequently accompaniedbyaPED,andtheprevalenceofaPEDhas beenreportedtobe10%-22%ineyeswithtypicalnAMD [39, 40] . Numerousstudiesshowedthatintravitrealbevacizumaband ranibizumabwereeffectiveandsafeforimprovingvisionin nAMDpatientswithPEDespeciallyserousPED,andthe anatomicresponseofthePEDmaynotcorrelatedirectly withthevisualoutcome [41] [42] [43] .However,Lommatzsch [40] pointedoutthatalthoughtreatmentwithbevacizumaband ranibizumabproducedbetter morphologicalandvisual results,onlyapartialflatteningofthePEDandcannot avoidingRPEtearsindicatingaworseprognosis.Introini [44] concludedthatthereisnoeffectivetherapyforPED secondarytonAMD,suggestingthatanti-VEGFtherapy couldachieveonlystabilizationofthedisease,butwithhigh riskofRPEtear.Moreover,Bolz [45] reportedthatahigh PEDatbaselinewasfoundtobeanegativepredictivefactor forvisualoutcomeinnAMD.Long-termtreatmentstrategies andprognosisshouldbedefined. 
